Recurrent respiratory papillomatosis causing chronic stridor and delayed speech in an 18-month-old boy

Adel Alharbi MD1, Derek Drummond MD2, Alfredo Pinto MD3, Valerie Kirk MD FRCPC1


Recurrence respiratory papillomatosis is a relatively uncommon disease that presents clinically with symptoms ranging from hoarseness to severe dyspnea. Human papilloma virus types 6 and 11 are important in the etiology of papillomas and are most probably transmitted from mother to child during birth. Although spontaneous remission is frequent, pulmonary spread and/or malignant transformation resulting in death has been reported. CO2 laser evaporation of papillomas and adjuvant drug therapy using lymphoblastoid interferon-alpha are the most common treatments. However, several other treatments have been tried, with varying success. In the present report, a case of laryngeal papillomatosis presenting with chronic stridor and delayed speech is described.

Key Words: Human papilloma virus; Pediatric laryngeal disease; Recurrent respiratory papillomatosis

CASE PRESENTATION

An 18-month-old boy was referred to the pulmonary service at the Alberta Children’s Hospital in Calgary from the emergency department with a history of noisy breathing since birth. He was accompanied by his father, who reported noisy breathing that was primarily inspiratory in nature and present continuously, but worsened with upper respiratory tract infections. There was no diurnal or positional variation noted. Accompanying symptoms included marked hoarseness, a very weak cry and a significant delay in speech development. Detailed sleep and feeding histories revealed no additional pertinent information. The boy was born via spontaneous vaginal delivery at term following an uneventful pregnancy. There was no available information regarding maternal history of genital human papilloma virus (HPV) infection. There was no history of prior hospital admission; however, there were frequent visits to doctors’ offices for evaluation of the stridor. Previous clinical diagnoses included asthma and laryngomalacia. Family history was noncontributory. On physical examination, the boy had no signs of respiratory distress at rest. Mild, persistent inspiratory stridor was noted, as well as an almost absent voice. There were no dysmorphic features and his weight was 10 kg (within the third to 10th percentile). His vital signs, including oxygen saturation, were within normal limits at rest. Chest examination was unremarkable with respect to inspection and auscultation. Aside from transmitted upper airway noises, no added sounds were noted. The remainder of his examination was normal with the exception of several small, raised, pale papular lesions on his back, which had been present since birth. Following examination, the boy was permitted to move about the small examining room to play. His stridor worsened and was accompanied by an increased respiratory rate, chest wall retractions and tracheal tug. Capillary blood gases were within normal limits (partial pressure of CO2 of 34 mmHg, bicarbonate concentration of 21 mmol/L and pH of 7.41).

Following evaluation in the pulmonary clinic, the boy had a nasendoscopy performed, with findings suggestive of laryngeal papillomatosis. Subsequent flexible bronchoscopy confirmed these findings and also confirmed that the lesions were localized to the larynx (Figure 1). At the time of the initial bronchoscopy, the first CO2 laser treatment was performed. Biopsy results confirmed the clinical diagnosis of laryngeal papillomatosis (Figure 2). The boy has had six subsequent laser treatments with a four to six week interval period, and he continues to be under the care of a pediatric otolaryngologist. He has also undergone a series of systemic treatments, including methotrexate and retinoic acid. Most recently, an injection of cidofovir into the larynx was given during emergency laser therapy for severe respiratory distress. He was well when last seen in the clinic, although his voice was still weak.

Correspondence: Dr Valerie Kirk, 1820 Richmond Road Southwest, Calgary, Alberta T2T 5C7. Telephone 403-943-2923, fax 403-943-7059, e-mail val.kirk@calgaryhealthregion.ca

PEDIATRIC CASE REPORT

Recurrent respiratory papillomatosis causing chronic stridor and delayed speech in an 18-month-old boy

Une papillomatose respiratoire récurrente responsable d’un stridor et d’un retard de langage chez un bébé de 18 mois

La papillomatose respiratoire récurrente est une maladie relativement peu fréquente, qui se manifeste cliniquement par des symptômes allant d’un enrouement à une dyspnée grave. Les papillomavirus de types 6 et 11 occupent une grande place dans l’étiologie des papillomes et sont probablement transmis de la mère à l’enfant pendant l’accouchement. La rémission spontanée est fréquente, mais on a déjà déclaré des cas de propagation pulmonaire ou de transformation maligne à l’issue fatale. Les traitements les plus courants sont le laser au gaz carbonique des papillomes et une chimiothérapie adjuvante au moyen d’interféron alpha lymphoblastoïde. Cependant, on a tenté plusieurs autres traitements, avec des résultats variés. Dans le présent rapport, on décrit un cas de papillomatose laryngée se manifestant par un stridor chronique et un retard de langage.

Key Words: Human papilloma virus; Pediatric laryngeal disease; Recurrent respiratory papillomatosis

1Department of Paediatrics, Division of Respiratory Medicine; 2Department of Paediatric General Surgery, Division of Otolaryngology; 3Department of Pathology, University of Calgary, Calgary, Alberta
DISCUSSION

Recurrent respiratory papillomatosis (RRP) is a relatively uncommon, nonmalignant yet aggressive disease that is characterized by papillomas present at various sites in the respiratory tract. Despite therapeutic measures and sometimes numerous surgical procedures, recurrence is frequent.

The onset of RRP may occur during either childhood or adulthood, with a bimodal age distribution showing the first peak in children younger than five years of age and the second peak in patients between 20 and 30 years of age. The juvenile-onset form of RRP is most common, with 25% of cases presenting during infancy (1). A classification system replacing the terms ‘juvenile’ and ‘adult’ with ‘aggressive’ and ‘non-aggressive’ was proposed by Doyle et al (2), and is probably more appropriate for clinical use because disease in the very youngest of patients is typically more aggressive than that seen in the older population. A national survey of both pediatric and general otolaryngologists reported an estimated 2354 new cases of pediatric RRP in the United States every year (incidence of 4.3 per 100,000) (1).

HPV DNA was first isolated in papillomas of the larynx from patients with both juvenile- and adult-onset RRP in 1982 (3). It was described as a naked, double-stranded, icosahedrally shaped virus with circular supercoiled DNA belonging to the papovavirus family (3). There are 90 subtypes of HPV known with only two subtypes responsible for most clinical cases of RRP (subtypes 6 and 11). These subtypes are also responsible for condyloma acuminata (genital warts), while subtypes 16 and 18 have been implicated as causative in cancer, particularly cancer of the uterine cervix (4). Transmission of HPV in RRP is thought to be multifactorial. However, in children, transmission most often occurs vertically due to active maternal HPV infection at the time of delivery (4). Other postulated routes include hematogenous spread and ascending transplacental inoculation (4). Mothers of affected children can recall by history active or prior HPV infection approximately 50% of the time. It has been estimated that 10% to 25% of women of childbearing age have latent or active HPV in cervical swabs (4). HPV DNA has been isolated in one-third to one-half of aerodigestive tract swabs of children born to affected mothers; however, the majority of these children do not develop disease. The risk of developing disease in this population is not precisely known but has been estimated to be one in 400 (5). The current medical literature generally does not support routine prophylactic Caesarian sections in women with HPV-positive swabs in the absence of other indications (5). However, in one study, only one of 109 children with RRP had a history of Caesarian birth, a rate much lower than that of the general population (5).

The most common presentation of RRP is hoarseness. Young children may also present with a weak cry, chronic cough, stridor or even complete aphonia (1,4). Distal disease can develop and portends a poorer prognosis due to its inaccessibility. Patients may also develop cavitary pulmonary lesions, which can lead to atelectasis, chronic infection, postobstructive pneumonia and sepsis (6). It appears that distal disease is more common with HPV type 11 infection (6). The lesions rarely undergo malignant degeneration, which is almost uniformly fatal (1).

Although the HPV lesions can be found anywhere in the aerodigestive tract, there appears to be a predilection for areas where there is a junction of squamous and ciliary epithelium. These areas include the limen vestibuli (junction of the nasal vestibule and the nasal cavity proper), the nasopharyngeal surface of the soft palate, the midzone of the laryngeal surface of the epiglottis, the upper and lower margins of the ventricle, the undersurface of the vocal folds, and the carinal and bronchial spurs (7). The diagnosis is usually confirmed by direct inspection and histological findings on biopsy specimens. The clinical finding on direct laryngoscopy is a verrucous outgrowth. Histologically, an epithelial projection with a fibrovascular core is seen with associated parakeratosis, koilocytosis and acanthosis (4).

Despite advances in medical therapy, surgery remains the primary treatment for RRP. The goal of surgery is the removal of as much disease as possible without damaging the adjacent or underlying tissue, which can lead to scarring, stenosis and loss of function (4). In an attempt to minimize the untoward
effects of surgery, various techniques and instrumentation have been described. These include endoscopic debulking with laryngeal forceps or microdebriders, excision with cold phonon-microsurgical instruments, and a combination of excision and ablation with the CO2 laser (8). While there are advocates for each technique, the CO2 laser and the laryngeal microdebrider are currently the most widely used (8).

While numerous adjuvant medical therapies have shown promise in the past, none have demonstrated a lasting or curative effect, and many have unfavourable side effects or toxicity profiles. These include interferon-alpha 2a, retinoic acid, indole-3-carbinol, and photodynamic therapy with dihematoporphyrin (1). More recently, the antiviral drug cidofovir has demonstrated efficacy against RRP and is considered a promising new adjuvant in the management of this disease. Cidofovir is an acyclic nucleoside phosphonate that has antiviral activity against a wide range of DNA viruses, including HPV. It exerts its effect through selective inhibition of viral DNA polymerases during viral replication. Cidofovir has been approved by the Food and Drug Administration for the treatment of cytomegalovirus retinitis in HIV patients at an intravenous dose of 5 mg/kg. When used intravenously at this dose, cidofovir can cause nephrotoxicity and neutropenia (9). However, recent studies suggest that these side effects are limited to intravenous use, with no evidence of renal, hepatic or hematological toxicity when injected into papillomatous lesions of the larynx or trachea (10).

CONCLUSIONS

RRP is caused by HPV subtypes 6 and 11. It affects people of all ages, but tends to be more aggressive in the young. Life-threatening airway obstruction may develop. The natural history is variable and poorly understood. Treatment is essentially palliative with surgical debulking.

REFERENCES

Submit your manuscripts at
http://www.hindawi.com